Alinity s Anti-HCV II - Clinical Evaluation Protocol

NACompletedINTERVENTIONAL
Enrollment

16,388

Participants

Timeline

Start Date

April 19, 2021

Primary Completion Date

June 21, 2021

Study Completion Date

August 5, 2021

Conditions
Healthy
Interventions
DEVICE

Alinity s Anti-HCV II

For all donor specimens with investigational Alinity s Anti-HCV II results that are discordant with final status after supplemental testing, an attempt will be made to obtain a follow-up whole blood specimen approximately 4 to 6 weeks after initial donation for further analysis.

Trial Locations (4)

37932

CSL Plasma Inc., Knoxville

55114

Innovative Blood Resources, Saint Paul

78201

QualTex Laboratories, San Antonio

98057

Bloodworks Northwest, Renton

All Listed Sponsors
lead

Abbott Transfusion Medicine

INDUSTRY